Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.67 |
| ▸ | BTK | Q06187 | 10/20 | 0.67 |
| ▸ | CD69 | Q07108 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | HRH2 | P25021 | 1/20 | 0.67 |
| ▸ | CDK7 | P50613 | 1/20 | 0.67 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.67 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.67 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.67 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.67 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.67 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169592 | 1.00 | JAK2 (0.67) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25170750 | 0.90 | BTK (0.69) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25167754 | 0.89 | JAK2 (0.69) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL30434060 | 0.89 | BTK (0.71) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25169912 | 0.89 | BTK (0.71) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL31169595 | 0.87 | BTK (0.66) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25174017 | 0.87 | BTK (0.66) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL30433480 | 0.86 | BTK (0.65) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25170629 | 0.86 | BTK (0.65) | JAK2BTKCD69CYP3A4HRH2 | |
| SCHEMBL25176776 | 0.85 | BTK (0.67) | JAK2BTKCD69CYP3A4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | JAK2 7/4885BTK 1/4885CD69 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.